Description
Pertuzumab, trastuzumab, and hyaluronidase-zzxf is approved to be given with docetaxel or other chemotherapy to treat: Breast cancer that is HER2 positive. It is used: As neoadjuvant therapy (to shrink the tumor before surgery) in adults with locally advanced, inflammatory, or early-stage breast cancer.
The fixed-dose combination is indicated for the treatment of early breast cancer (EBC):
Use in combination with chemotherapy for
-
- the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than two cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer;
- the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
and for the treatment of metastatic breast cancer (MBC):
- Use in combination with docetaxel for the treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
How can 1 go about obtaining pertuzumab, trastuzumab, and hyaluronidase-zzxf injection?
PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020
If PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
References
- Full prescribing information [FDA]: Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [PDF] Genentech, June 29, 2020
- FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional FDA press release, June 29, 2020
- Phesgo EMA product information sheet, cited on Jan 25, 2021